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The powerful activating receptor NKG2D is expressed by natural
killer (NK) cells and promotes cytotoxic lysis of cancer cells
expressing NKG2D ligands (NKG2D-Ls). We report the effective
induction of NKG2D-Ls, achieved with the naturally occurring
polyphenol resveratrol, in a broad range of leukemia cells. In
this study, resveratrol upregulated the NKG2D-Ls MHC class I
chain-related proteins MICA and MICB, and UL16-binding
proteins ULBP1, ULBP2, and ULBP3 in most of the leukemia cells
analyzed. Ligand upregulation induced by resveratrol was
impaired by pharmacological and genetic disruption of ataxia–
telangiectasia mutated kinase, the main regulator of NKG2D-L
expression. Leukemia cells treated with resveratrol were more
susceptible to killing by NK cells than untreated cells, and the
enhanced cytotoxicity of NK cells was blocked by treatment of
NK cells with anti-NKG2D mAbs. Interestingly, resveratrol consis-
tently upregulated the NKG2D receptor expression and enhanced
NKG2D-mediated functions in resting NK cells obtained from
healthy individuals. Therefore, resveratrol has attractive immu-
notherapeutic potential. (Cancer Sci 2013; 104: 657–662)
T he potent activating receptor NKG2D is expressed oneffector cells of both the innate and adaptive immune
system such as natural killer (NK) cells, NK T cells, cd T
cells, and some subsets of CD8+ T cells. The NKG2D receptor
plays pivotal roles in immunosurveillance of viral infections
and cancer.(1) NKG2D recognizes diverse and structurally dif-
ferent ligands, including the MHC class I chain-related pro-
teins (MICA and MICB), the UL16-binding proteins (ULBP1
to 5) and retinoic acid early transcript.(2) The NKG2D ligand
(NKG2D-L) transcripts are detectable in numerous normal
healthy tissues; however, they are either absent or poorly
expressed at the protein level.(3) In response to a variety of cell
stress stimuli, such as viral infections and tumorigenesis,
NKG2D-Ls are upregulated on the cell surface rendering
ligands expressing cells more sensitive to destruction by NK
cells through the NKG2D receptor.(1,2) Stress signals, particu-
larly those associated with double-strand breaks in DNA, upre-
gulate the NKG2D ligand expression through the activation of
ataxia–telangiectasia mutated (ATM) signals.(4) Therefore,
ATM has been postulated to be the most important regulator
of NKG2D-L expression.(4)
Resveratrol is a polyphenol found in grapes and other
sources that possesses numerous health benefits, including
anti-inflammatory, anti-aging, and antitumor activities.(5) Res-
veratrol is a multitarget agent capable of modulating several
proteins, including those in the nuclear factor-jB, JAK2 ⁄ signal
transducer and activator of transcription-3 (STAT3), and
protein kinase B pathways.(5–8) Interestingly, resveratrol
induces non-mutagenic DNA damage and direct activation of
ATM in tumor cells(9,10); however, it is unknown whether
ATM activation induced by resveratrol is associated with the
induction of NKG2D-Ls in malignant cells.
This study showed that resveratrol not only activates ATM
in leukemia cells, but also induces the expression of NKG2D-
Ls in several leukemia cells, rendering them more sensitive to
NKG2D-mediated lysis by NK cells. Given the crucial role of
the NKG2D system in tumor immunosurveillance, these find-
ings could account for the reported chemopreventive properties
of this polyphenolic compound.
Materials and Methods
Cell lines. Molt4, THP1, KG1, and Jurkat cell lines were pur-
chased from the Health Science Research Resources Bank
(Ibaraki, Osaka, Japan). HL60 and Daudi cells were purchased
from ATCC (Rockville, MD, USA). The chronic myeloid
leukemia cell line OUN1 and the myelodysplastic syndrome
cell line TF1 were provided by Dr M. Yasukawa of Ehime
University (Matsuyama, Japan) and Dr S. Ogawa of the Uni-
versity of Tokyo (Tokyo, Japan), respectively. The TF1 cells
were cultured in Iscove’s modified Dulbecco’s medium supple-
mented with 20% FBS and granulocyte ⁄macrophage colony
stimulating factors. All other cells were cultured in RPMI-
1640 medium supplemented with 10% FBS and 1% penicillin
and streptomycin.
Reagents. Resveratrol was purchased from Sigma (St. Louis,
MO, USA) and solubilized in DMSO. The antibodies directed
against total STAT3, ERK1 ⁄2, JNK1 ⁄2, and Chk2, as well as
those against phosphorylated STAT3, ERK1 ⁄2, JNK1 ⁄2, and
Chk2 proteins, were purchased from Cell Signaling Technol-
ogy (Tokyo, Japan). Anti-GAPDH was purchased from Gene-
tex (Los Angeles, CA, USA).
Natural killer cell preparation. Peripheral blood mononuclear
cells were isolated using Lymphoprep (Pharmacia Biotech,
Uppsala, Sweden) from heparinized blood samples of healthy
volunteers collected under a protocol approved by the Institu-
tional Review Board of Kanazawa University (Kanazawa,
Japan). The NK cell fraction was purified using the untouched
NK isolation kit (Invitrogen, Carlsbad, CA, USA). Flow
cytometry confirmed that these cells were more than 95%
CD3 CD56+ CD16+ NK cells. The cells (1 9 106 cells ⁄mL)
were resuspended in RPMI medium supplemented with 20%
FBS and cultured for 24 or 48 h in the presence of several
concentrations of resveratrol or vehicle (0.7% DMSO) and
analyzed for NKG2D receptor expression by Western blotting
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and flow cytometry. A detailed description of the effect of res-
veratrol against activated NK cells or activated T cells is
described in the supporting information (Fig. S1).
Leukemia cell culture and treatment with resveratrol. In preli-
minary experiments, leukemia cells lines (1 9 106 cells ⁄mL)
were cultured in the presence of several concentrations of res-
veratrol to determine the maximal dose of resveratrol that did
not induce cell apoptosis as assessed with annexin V staining
and flow cytometry analyses. As a large number of NB4,
KH88, and Daudi cells underwent apoptosis after treatment
with resveratrol, those cell lines were excluded from this
study. The 37 lM concentration of resveratrol was selected
and used throughout the study because it was found to effec-
tively modulate NKG2D-Ls in Molt4, THP1, KG1, Jurkat,
HL60, OUN1, and TF1 cells without inducing apoptosis. Res-
veratrol treated and untreated cells were cultured for 48 h and
their cell surface expression of NKG2D-Ls was analyzed with
flow cytometry. In some experiments, the cells were cultured
for 12 or 24 h and harvested for RT-PCR analyses.
Flow cytometry. Detection of CD3, CD56, CD16, MICA ⁄B
(BD Biosciences, San Jose, CA, USA) and NKG2D (Beckman
Coulter, Brea, CA, USA) was carried out by staining the cells
with appropriate fluorochrome mAbs. Detection of ULBP
ligands was carried out with anti-ULBP1, ULBP2, and ULBP3
mAbs (R&D Biosystems, Minneapolis, MN, USA) which were
FITC labeled with the SureLINK FITC labeling kit (KPL, Gai-
thersburg, MD, USA). Data acquisition and flow cytometry
analyses were carried out with a BD FACSCalibur instrument
using the CellQuest software package (BD Biosciences) and
analyzed using the FlowJo software package (Tri Star, Inc.,
Ashland, OR, USA). The NKG2D expression level on NK cells,
as well as that of NKG2D-Ls, was determined according to the
mean fluorescence intensity (MFI) calculated by subtracting the
MFI in the cells stained with the isotype antibody from the MFI
in the corresponding cells stained with the specific antibodies.
The presence of phosphorylated ATM in the leukemia cells was
assessed using the FlowCellect Cell Cycle Checkpoint ATM
DNA Damage Kit (Millipore, Billerica, MA, USA). Cell cycle
analysis was assessed as previously described.(7)
Quantitative RT-PCR. Total RNA was extracted from the cells
using the Tripure RNA isolation agent following the manufac-
turer’s instructions (Roche, Basel, Switzerland). Complemen-
tary DNA synthesis was carried out using the QuantiTect
Reverse Transcription kit (Qiagen, Hilden, Germany). The
NKG2D mRNA levels were measured as previously
described.(11) Amplification of ULBP1, ULBP2, ULBP3, and
MICA cDNA was monitored using the SYBR Premix Ex Taq
kit (Takara, Kyoto, Japan) on a StepOne plus instrument
(Applied Biosystems, Carlsbad, CA, USA) using the primers
described in a previous report.(12) The amount of NKG2D-L
transcripts and that of NKG2D receptor relative to b-actin and
GAPDH mRNA, respectively, were calculated according to the
comparative CT method using the relative expression function
included in the StepOne version 2.2 software package (Applied
Biosystems). Untreated cells were used as calibrators.
Construction of shRNA ATM lentivirus delivery system. A
target sequence of the human ATM was generated by inserting
the annealed oligonucleotides: 5′-ACCGAAGAGAGACTGCT
ACCAAGGCGAACCTTGGTAGCAGTCTCTCTT-3′ and 5′-
AAAAAAGAGAGACTGCTACCAAGGTTCGCCTTGGTAG-
CAGTCTCTCTTC-3′ into the pENTR ⁄U6 BLOCK-iT plasmid
(Invitrogen) to generate the pENTR ⁄U6-ATM-shRNA vector.
A recombination reaction using LR clonase was completed to
transfer the pENTR ⁄ATM-shRNA or the negative control
pENTR ⁄U6-GW ⁄ lacZshRNA cassette(13) into the lentivirus
delivery pLenti6 ⁄BLOCK-iT-DEST (Invitrogen) to construct
pLenti6 ⁄Block-iT pENTR ⁄ATM-shRNA (designated thereafter
as shRNA-ATM) or pLenti6 ⁄Block-iT pENTR ⁄U6-GW ⁄ lac-
ZshRNA (designated thereafter as shRNA-NC). This lentivirus
vector was used to establish ATM-deficient OUN1 and Molt4
cells, as previously described.(13) Blasticidin-resistant clones
transduced with shRNA-ATM or shRNA-NC from both cell
lines were selected, expanded, and screened for ATM expres-
sion and sensitivity to resveratrol.
Measurement of cytokine and Granzyme B secretion. The
levels of tumor necrosis factor-a (TNF-a), c-interferon, and
Granzyme B secreted by primary NK cells were assessed as
previously described(11) with minor changes as follows. The
NK cells were cultured for 24 h in the presence or absence of
resveratrol. The cells were then resuspended (2 9 106 cells
⁄mL) in RPMI medium supplemented with 100 U ⁄mL interleu-
kin-2 and plated in 96-well plates coated with human IgG or a
mixture composed of 5 lg ⁄mL each of the following recombi-
nant human NKG2D ligands (Fc chimeras, MICA, ULBP1,
and ULBP2 [R&D Systems]) and cultured for another 48 h.
The levels of TNF-a and Granzyme B in the culture superna-
tants were determined using specific ELISA assays (Mabtech,
Nacka Strand, Sweden).
Natural killer cell cytotoxicity assay. The cytotoxic activity of
NK cells was measured using a 51Cr release assay.(12) Target
cells were pre-incubated with resveratrol or vehicle (0.7%
DMSO) for 48 h. In the blocking experiments, the effector
cells were incubated with 5 lg murine anti-NKG2D mAbs
(clone 149810) or an equal amount of isotype control antibod-
ies (both from R&D Systems) for 30 min at 37°C before being
incubated with the target cells. The effector cells were co-incu-
bated with the indicated effector:target ratio. The percentage
of specific lysis was determined as previously described.(12)
Western blotting. Sample preparation and protein detection
were carried out as described in a previous report.(7) Where
indicated, comparative blot intensities were assessed using
ImageJ software (National Institutes of Health, Bethesda, MD,
USA).
Statistical analysis. All data are reported as the mean  SE.
When comparisons were made between two different groups,
statistical significance was determined using Student’s t-test.
The statistical significance of multiple comparisons was deter-
mined using a one-way ANOVA. The data were considered
statistically significant at P  0.05. All statistical analyses
were carried out using the Prism software package (GraphPad,
San Diego, CA, USA).
Results
Resveratrol activates ATM signaling in leukemia cells. To
investigate the potential activation of ATM signaling in leu-
kemia cells by resveratrol, cells were treated with subtoxic
doses of resveratrol then analyzed with flow cytometry using
an antibody specific for phosphorylated ATM on Ser1981. A
consistent activation of ATM was detected in the cells treated
with resveratrol but not in those treated with vehicle
(Fig. 1a). This effect was followed by dose-dependent
phosphorylation of the ATM substrate Chk2 on Thr68 in the
resveratrol-treated cells (Fig. 1b). Remarkably, at 37 lM, res-
veratrol induced no significant increases in the number of
apoptotic cells (not shown). In addition, resveratrol vigorously
induced G1 or S cell cycle arrest in the leukemia cells. In
response to resveratrol treatment, Molt4 and THP1 cells were
arrested in the G1 phase, whereas other cells, such as TF1
and KG1 cells, were arrested in the S phase of the cell cycle
(Fig. 1c).
Resveratrol increases expression of NKG2D-Ls in leukemia cells.
To substantiate whether the resveratrol-induced activation of
ATM signaling results in the induction of NKG2D-Ls in leuke-
mia cells, the expression of NKG2D-L transcripts was assessed
with an RT-PCR analysis. By 12 h, resveratrol induced insig-
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nificant changes in NKG2D-L transcripts (not shown); how-
ever, after 24 h of treatment, resveratrol induced a variable
increase in NKG2D-L transcripts, including MICA, ULBP1,
ULBP2, and ULBP3, in the leukemia cells (Fig. S2). A flow
cytometry analysis revealed that resveratrol induced heteroge-
neous but consistent enhancement of the expression of
NKG2D-Ls in most of the cell lines evaluated including
OUN1, TF1, Molt4, and KG1 cells (Fig. 2a). Notably, PBMCs
from healthy donors treated with resveratrol did not upregulate
NKG2D-Ls (Fig. 2b). Consistent with previous reports,(14)
ULBP1 was detectable in untreated PBMCs; however, its
expression level was not modified by resveratrol.
Role of ATM signaling in resveratrol-induced NKG2D-L
expression. A critical role for ATM kinase was suggested by
the finding that resveratrol-induced ligand upregulation was
attenuated by pretreatment of leukemia cells with caffeine, a
strong inhibitor of ATM signaling(4,12) (Fig. 3a). Next, ATM-
deficient leukemia cell lines were established using lentivirus
delivery of a shRNA targeting the ATM gene. The effective down-
(a) (b)
(c)
Fig. 1. Resveratrol activates ataxia–telangiectasia
mutated kinase (ATM) signaling in leukemia cells.
(a) Leukemia cells were treated with resveratrol or
vehicle for 6 h then stained with an antibody
specific for phosphorylated ATM (at Ser188) and
analyzed with flow cytometry. (b) Leukemia cells
were treated for 24 h with the indicated dose of
resveratrol and the expression of activated Chk2 in
the cellular lysates was assessed with Western
blotting. Representative results using Molt4 and
OUN1 cells are shown in panels (a and b).
(c) Leukemia cells were treated with resveratrol for
12 h and a cell cycle analysis was carried out using
flow cytometry. Representative results of three
independent experiments are shown.
(a)
(b)
Fig. 2. Resveratrol induces the expression of NKG2D ligands in leuke-
mia cells. (a) Leukemia cells were treated with resveratrol or vehicle
for 48 h and stained with antibodies specific for MHC class I chain-
related protein MICA and UL16-binding proteins ULBP1, ULBP2, and
ULBP3 and analyzed with flow cytometry. Representative results of
cells expressing MICA and ULBP2 are shown. (b) PBMCs from three
healthy donors were treated and analyzed as in panel (a). Representa-
tive results of the NKG2D ligand expression in cells obtained from a




Fig. 3. Role of ataxia–telangiectasia mutated kinase (ATM) signaling
in NKG2D ligand (NKG2D-L) expression induced by resveratrol. (a) Leu-
kemia cells were treated with caffeine for 2 h then cultured in the
presence of resveratrol for another 48 h. The NKG2D-L expression was
assessed with flow cytometry. A representative result of the NKG2D-L
expression in OUN1 cells is shown. (b) The expression of ATM in Molt4
or OUN1 cells. Whole-cell extracts from WT or shRNA transduced
Molt4 and OUN1 cells were probed for ATM expression using Western
blotting. Representative figures of five independent experiments are
shown: lane 1, WT cells; lane 2, shRNA-ATM transduced cells; lane 3,
cells transduced with shRNA-NC. (c) Wild-type or shRNA transduced
Molt4 and OUN1 cells were cultured for 48 h in the presence or
absence of resveratrol and their expression of NKG2D-Ls (MHC class I
chain-related protein MICA and UL16-binding protein ULBP2) was
assessed by flow cytometry. Data are expressed as fold of increase in
mean fluorescence intensity of ULBP2 and MICA in leukemia cells after
treatment with resveratrol. Error bars represent SEM of three indepen-
dent experiments.
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regulation of ATM in OUN1 and Molt4 cells was consistently
achieved, as shown by Western blotting (Fig. 3b). In contrast to
wild-type cells or the shRNA-NC transfected counterparts, the
ATM knockdown cells did not upregulate NKG2D-Ls after
undergoing resveratrol treatment (Fig. 3c). These results indi-
cate that functional ATM is required for the resveratrol-induced
expression of NKG2D-Ls in leukemia cells. Notably, p53 was
not required for NKG2D-L induction by resveratrol, as indi-
cated by the effective ligand upregulation in p53-null cell line
HL60 and in Jurkat cells, which harbor non-functional p53, in
response to resveratrol treatment (Fig. S3a). This was supported
by the inefficacy of the p53 inhibitor pifithrin-a to prevent the
overexpression of ULBP2 and MICA in response to resveratrol
treatment in the p53 active Molt4 cells (Fig. S3b). Of note, in
response to resveratrol treatment, Jurkat and HL60 cells were
arrested in the S phase of the cell cycle (Fig. S3c).
Resveratrol-induced NKG2D-L expression enhances NK cell lysis
of leukemia cells. Remarkably, the pretreatment of leukemia
cells with resveratrol significantly resulted in an increase in
the sensitivity of these cells to killing by NK cells. Notably,
the leukemia cell sensitization to NK cell killing appears to
be proportional to the levels of NKG2D-Ls induced by resve-
ratrol in those cells. The THP1 cells treated with resveratrol
resulted in a weak induction of NKG2D-Ls (Fig. 2a) and only
a marginal increase in their sensitivity to NK cells killing
(Fig. 4a, left panel). Conversely, NK cells vigorously killed
Molt4 cells (Fig. 4a, right panel), which strongly upregulated
NKG2D-Ls after treatment with resveratrol (Fig. 2a). The
treatment of other leukemia cells including OUN1, TF1, and
KG1 cells with resveratrol resulted in a variable but signifi-
cant increase in their cytotoxicity by NK cells (Fig. 4b). The
increase in leukemia cell lysis was significantly reduced by
pretreating NK cells with blocking anti-NKG2D mAbs but
not with isotype murine IgG (Fig. 4), supporting the involve-
ment of an NKG2D receptor ⁄NKG2D-L interaction.
Effects of resveratrol on primary NK cells. The effects of
resveratrol on NK cells from healthy individuals were investi-
gated. As shown in Figure 5(a,b), resveratrol induced variable
but consistent enhancement of the NKG2D expression at pro-
tein level. This effect was also evident at transcriptional level
(Fig. 5c). Notably, at the same dose that was effective in
inducing NKG2D-Ls in leukemia cells, resveratrol had no
significant effects on the viability of in vitro activated NK
cells; however, cells treated with 50 lM resveratrol proliferate
(a)
(b)
Fig. 4. Resveratrol enhances NKG2D-mediated
killing of leukemia cells by natural killer (NK) cells.
(a) THP1 and Molt4 cells were treated with
resveratrol for 48 h then used as targets of resting
NK cells in a Cr release assay. (b) Leukemia cells
OUN1, Molt4, Jurkat, and KG1 were treated with
resveratrol for 48 h then used as targets of resting
NK cells in a Cr release assay at a 10:1 effector:
target ratio. Data shown are average cytotoxicity of





Fig. 5. Resveratrol modulates the expression of
NKG2D receptor in natural killer (NK) cells. (a) NK
cells from healthy donors were cultured in the
presence or absence of resveratrol for 48 h and
their expression of NKG2D receptors were assessed
with flow cytometry. A representative result is
shown in the left panel and summarized data from
four donors are shown in the right panel. (b) NK
cells were treated as in panel (a) and their
expression of NKG2D receptors was examined with
Western blotting using anti-NKG2D mAb (clone
149810). The same blots were stripped and
reprobed with anti-GAPDH antibodies equal
protein loading. A representative result of three
independent experiments is shown. Densitometric
analysis of the bands obtained in three
independent experiments (mean  SEM) is shown
in the right panel. (c) NK cells were treated with
resveratrol for 24 h and the levels of NKG2D
transcripts were assessed using RT-PCR. Expression
levels were normalized to GAPDH. Data represent
mean  SEM from four donors are shown.
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less efficiently and doses higher than 100 lM resveratrol sig-
nificantly impaired the viability of NK cells (Fig. S1a). These
effects were also evident in activated T cells (Fig. S1b,c).
The expression levels of phosphorylated protein kinases
ERK1 ⁄2 and JNK1 ⁄2, as well as that of STAT3, in resvera-
trol-treated NK cells were also examined. In fresh NK cells,
resveratrol induced a modest increase in the phosphorylation
state of ERK1 ⁄2 and robust activation of JNK1 ⁄2 (Fig. 6a),
consistent with the reported effects of resveratrol in the NK92
cell line.(26) Of note, resveratrol did not affect STAT3 activity
in NK cells. Remarkably, resveratrol-treated primary NK cells
secreted higher levels of TNF-a and Granzyme B (Fig. 6b,c)
in response to NKG2D receptor ligation by plate-coated
NKG2D-Ls, thus indicating that resveratrol-induced NKG2D
upregulation has functional implications.
Discussion
The potent activator receptor NKG2D triggers NK cell cyto-
toxicity against NKG2D-Ls expressing target cells. The spe-
cific interaction of the NKG2D receptor with its ligands plays
a critical role in tumor surveillance; hence, pharmacological
induction of NKG2D-Ls in tumor cells is an attractive immu-
notherapeutic approach. The present study showed that resve-
ratrol, a naturally occurring polyphenol, effectively induces the
expression of NKG2D-Ls in leukemia cells. Consequently,
resveratrol-treated cells are sensitized to NKG2D receptor-
dependent killing by NK cells. In addition, we found that resve-
ratrol modulates the expression of NKG2D receptor in NK cells.
Our mechanistic studies indicated that ATM signaling activa-
tion is required for resveratrol-induced NKG2D-L upregulation
in leukemia cells. This finding is consistent with previous
reports suggesting that ATM is a key player in ligand
overexpression in response to genotoxic stress signals such as
those induced by ionizing radiation and hydroxyurea, valproic
acid, and other histone deacetylase inhibitors.(4,12,15) In addi-
tion, our data showing resveratrol induced the activation of
ATM signaling in leukemia cells is consistent with previous
reports showing that resveratrol is a direct activator of ATM
signaling in various cellular systems.(9,16) A serine–threonine
kinase, ATM phosphorylates specific targets, including p53,
Chk2, BRCA1, Nbs1, and other substrates that play critical
roles in the regulation of apoptosis and DNA repair as well as
cell cycle arrest at G1 ⁄S, intra-S, and G2 ⁄M checkpoints.(4,17,18)
Resveratrol has been reported to modulate key regulators of the
cell cycle, thus resulting in G1 ⁄S, S, and G2 ⁄M cell cycle
arrest.(19) Its effects on specific cell cycle phases vary consider-
ably among cell types and may be dependent on both the con-
centration of resveratrol and the characteristics of the target
cells.(19,20) Notably, resveratrol-induced ATM activation is
accompanied by S phase arrest in ovarian tumor cells and
malignant B cells.(16,21) This is consistent with our finding that
resveratrol-induced ATM activation is associated with G1 or S
arrest in leukemia cells.
Due to its pivotal role in the regulation of cell cycle
progression, DNA damage response through ATM activation
constitutes an anticancer barrier in early human tumorigene-
sis.(18) In addition, the NKG2D receptor ⁄NKG2D-L interac-
tion plays a critical role in tumor immunosurveillance(1) and
several in vivo studies support the efficacy of resveratrol in
the prevention of tumor development.(5,22) Therefore, our data
are consistent with the notion that the ATM-mediated upregu-
lation of NKG2D-Ls in transforming cells induced by
resveratrol may account for the reported chemopreventive
properties of this polyphenolic compound. The release of
NKG2D-Ls from tumor cells, either within exosomes(23) or in
soluble form,(24) constitutes an efficient strategy by cancer
cells to evade NKG2D-mediated killing. It is unknown
whether resveratrol-induced NKG2D-Ls in leukemia cells are
accompanied by ligand shedding from tumor cells, which
may impair the NK cell function, particularly in patients with
advanced disease.
Several agents capable of enhancing NKG2D-Ls in tumor
cells have been reported thus far,(4,12) however, resveratrol
constitutes the first agent capable of modulating NKG2D
receptors in effector NK cells. In fresh NK cells, resveratrol
induced an activated phenotype characterized by a higher
NKG2D expression, more efficient secretion of cytokines, and
activation of ERK1 ⁄2 and JNK1 ⁄2 kinases, consistent with
previous observations in NK92 cells and other cellular systems
treated with resveratrol.(25–27)
The current study showed that 37 lM resveratrol is optimal
for inducing NKG2D-Ls expression in leukemia cells. Similar
concentrations of resveratrol are safe for inducing the clonal
growth of normal hematopoietic progenitor cells(28,29) and are
non-toxic to human PBMCs(8,29); however, 50 lM or more of
resveratrol impairs the proliferation of activated NK cells and
T cells in vitro (Fig. S1) and that of highly proliferating nor-
mal cells.(29) The results of phase I clinical trials show that up
to 5 g ⁄day of resveratrol is safe and well-tolerated and does
not result in plasma concentrations above 50 lM.(30,31)
Accordingly, it is therefore unlikely that in vivo treatment with
resveratrol is harmful for normal cells.
In summary, this study showed that resveratrol enhances the
cytotoxicity of NK cells against leukemia cells through the
modulation of the NKG2D receptor ⁄NKG2D-L system. This
mechanistic finding, together with recent reports from clinical
trials showing the safety of resveratrol in humans, supports the
use of this polyphenol as a potential immunotherapeutic agent.
(a) (b)
(c)
Fig. 6. Resveratrol modulates the expression of protein kinases asso-
ciated with natural killer (NK) cell activation. (a) NK cells were treated
with the indicated concentrations of resveratrol for 24 h and their
expressions of phosphorylated ERK1 ⁄ 2, JNK1 ⁄ 2, and signal transducer
and activator of transcription-3 (STAT3) were examined with Western
blotting. Representative results of three independent experiments are
shown. Natural killer cells were cultured for 24 h in the presence or
absence of resveratrol. The cells were harvested and cultured for 48 h
in plates coated with human IgG or a mixture of five recombinant
human NKG2D ligands. The levels of tumor necrosis factor-a (TNF-a)
(b) and Granzyme B (c) released into the culture medium were mea-
sured using ELISA. Mean  SEM of three independent experiments is
shown.
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